Cbio’s mission is to develop and bring next-generation T-cell therapies to cancer patients worldwide.
Pursuing our mission, we are developing next generation T-cell therapies for solid tumors, accounting for 90% of all cancers. Our transformative new T-cell product – novoleucel – enables more patients to be treated due to its minimal invasiveness, with a broader T-cell repertoire of more stemness-like (revitalized) T-cells, both features that are linked to improved clinical outcome and survival for late-stage cancer patients.